Navigation Links
ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
Date:7/2/2010

MINNEAPOLIS, July 2 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD) today announced that it has commenced a tender offer to holders of certain outstanding warrants to provide additional consideration for the exercise of such warrants.  The warrants subject to the tender offer are 1,752,760 publicly traded warrants and 2,752,947 unregistered warrants to purchase common stock that were issued on January 12, 2009 and will expire on January 7, 2014.  Also subject to the tender offer are 1,244,829 publicly traded warrants to purchase common stock that were issued on November 12, 2009 and will expire on November 12, 2012.  The tender offer commenced on Friday, July 2, 2010.

ProUroCare is offering to holders of the subject warrants the opportunity to exercise their existing warrants and receive, in addition to the shares of common stock purchased upon exercise, new, three-year replacement warrants.  The replacement warrants will have an exercise price of $1.30 per share and will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.  ProUroCare must provide 30 days' prior written notice of a decision to redeem either the existing or replacement warrants.  Warrants not exercised during this 30-day period will be redeemed at $0.01 per warrant.  The purpose of the offer is to provide an incentive to exercise the subject warrants and thereby raise additional capital for ProUroCare.  

The offer is scheduled to expire at 4:00 P.M. Central Time on August 2, 2010, unless ProUroCare elects to extend the offer.  Subject warrants that are not tendered will retain their original terms including the $1.30 exercise price, expiration date and redemption terms.  Warrant holders may withdraw any tendered warrants before the expiration of the offer period and retain them on their original terms.  The subject warrants issued on January 12, 2009 may be redeemed at any time prior to expiration by ProUroCare.  The subject warrants issued on November 12, 2009 will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.

The Offer Letter/Prospectus will be received by subject warrant holders in the near future (except for those who reside in states where the offer is not permitted).  For questions or assistance, or to request additional copies of the Offer Letter/Prospectus, which will be provided at ProUroCare's expense, warrant holders should contact Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam (DRE).  Based in Minneapolis, Minn., ProUroCare's common stock is quoted on the OTCBB.

ProUroCare Medical, Inc. has filed a Registration Statement on Form S-4 (including a prospectus) and a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the "SEC") for the tender offer and offering to which this communication relates. Before you accept the offer, you should read the Offer Letter/Prospectus in that registration statement, the related Letter of Transmittal, the Schedule TO and other documents ProUroCare has filed with the SEC, as well as any amendments or supplements thereto, for more complete information about ProUroCare, the tender offer and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, ProUroCare will arrange to send you the Offer Letter/Prospectus and related documents, the Registration Statement on Form S-4 or the Tender Offer Statement on Schedule TO upon request by contacting Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161. There shall there be no sales of the warrants or underlying common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.   


'/>"/>
SOURCE ProUroCare Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Secures $885,000 in Financing
2. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
3. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
4. ProUroCare Medical Elects Two New Directors
5. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
6. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
7. ProUroCare Medical Inc. Announces Pricing of Equity Offering
8. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
9. Seniors and People with Disabilities Will Pay Steep Price for Medicares Competitive Bidding Program for Home Medical Equipment
10. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
11. Concord Medical Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
Breaking Medicine Technology:
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has ... camp held at Oregon State University this summer. Employing world-class rugby figures, including former ... all skill levels with training on key fundamentals, match play, fitness and more. , ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery Channel. ... vision of becoming a leader in optimized drug discovery through innovative cellular analysis. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of ... for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: ... Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, and ...
(Date:5/6/2016)... ... ... Canadian author Mark Black is a speaker, author, and life strategy coach who ... … with the help of his publisher Strategic Book Group and its subsidiary Publish ... bed waiting for a miracle: He needed a heart and double-lung transplant. From this came ...
Breaking Medicine News(10 mins):